Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 48Multiple Myeloma 39Lymphoma, Large B-Cell, Diffuse 38Burkitt Lymphoma 34Lymphoma 31Leukemia, Myeloid, Acute 31Lymphoma, Non-Hodgkin 29Recurrence 27Breast Neoplasms 27Neoplasms 23Lymphoma, B-Cell 23Myelodysplastic Syndromes 22Leukemia, Lymphocytic, Chronic, B-Cell 22Lymphoma, Follicular 20Hodgkin Disease 18Triple Negative Breast Neoplasms 17Melanoma 17Leukemia 17Ovarian Neoplasms 16Hematologic Neoplasms 15Neuroblastoma 14Lymphoma, Mantle-Cell 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 12Pancreatic Neoplasms 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 12Leukemia, Biphenotypic, Acute 11Neoplasm Metastasis 10Lymphoma, B-Cell, Marginal Zone 10Leukemia, Myelomonocytic, Chronic 10Sarcoma 9

Interventions

trastuzumab biosimilar HLX02 2ribociclib 2pertuzumab 2Trastuzumab 2Taxes 2Specimen Handling 2Paclitaxel 2PF-05280014 2Ontruzant 2Ogivri 2Magnetic Resonance Spectroscopy 2Drug Therapy 2Docetaxel 22C4 antibody 2tucatinib 1exemestane 1durvalumab 1Surgical Procedures, Operative 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Radiotherapy 1Radiation 1Mastectomy, Segmental 1Mastectomy 1Letrozole 1Immunoglobulin G 1Genetic Testing 1Fulvestrant 1Fluorodeoxyglucose F18 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anatomic Stage II Breast Cancer AJCC v8 × Cyclophosphamide × 90 days × Clear all
NCT06058377 2026-06-03

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

National Cancer Institute (NCI)

Phase 3 Recruiting
3,680 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡